Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Almost a third of people report lingering symptom 6-12 months after COVID-19 -study

Published 03/04/2022, 12:07 PM
Updated 03/04/2022, 12:11 PM
© Reuters. FILE PHOTO: A patient suffering from Long COVID is examined in the post-coronavirus disease (COVID-19) clinic of Ichilov Hospital in Tel Aviv, Israel, February 21, 2022.  REUTERS/Amir Cohen/File Photo

By Jennifer Rigby

(Reuters) - Almost a third of people report at least one ongoing symptom between 6 and 12 months after their coronavirus infection, a survey of 152,000 people in Denmark has found.

The study includes one of the largest groups yet of people who were not hospitalised with COVID, and followed them for longer than other major studies, the researchers from Denmark's State Serum Institute (SSI) said.

The questionnaire-based study suggested that the most commonly reported long-term symptoms were changes in sense of smell and taste, as well as fatigue.

Conducted between September 2020 and April 2021, well before the recent Omicron variant surge, the survey compared the responses of 61,002 people who had tested positive for the coronavirus six, nine or 12 months before with those of 91,878 people who had tested negative.

In total, 29.6% of the respondents who had tested positive reported at least one ongoing physical symptom 6 to 12 months after infection, compared to 13% in the control group.

Just over half (53.1%) of those with positive tests said they had experienced either mental or physical exhaustion, sleep problems or cognitive problems within the 6 to 12 months after infection. That compared to 11.5% in the control group.

New diagnoses of anxiety and depression were also more common among those with a history of SARS-CoV-2 infection, the study showed.

The study was published as a pre-print and has not yet been peer reviewed.

Study author Anders Peter Hviid, an epidemiology professor at SSI, said the results are another sign that the long tail of COVID-19 should be considered by policy makers.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"It's something you should take into account when you are weighing up the risks and benefits of... the interventions you are making, and vaccinations," he said in a phone interview, stressing that more studies are needed.

Estimates on the prevalence of what is known as long COVID vary. The World Health Organization (WHO) calls the syndrome Post-COVID-19 condition and defines it as ongoing symptoms - including fatigue or shortness of breath, among others - three months after the initial infection that last at least two months.

The WHO estimates that between 10% and 20% of people are affected by that point and says more work is needed on the longer-term prognosis.

David Strain, lecturer at the University of Exeter Medical School in the UK who was not involved in the study, called the report "really concerning."

“If Omicron is causing long Covid at the same rate as these earlier variants, we could be looking at a major crisis over the next 12 months given the number of people who have been exposed to this virus,” he said.

Latest comments

Vaccine injures reported for 68% who received them
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.